C12N 2710/24032
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2710/24032 (Use of virus as therapeutic agent, other than vaccine) appears on 23 US grants and 50 published applications in this corpus.
Search patents in C12N- Granted patents
- 23
- Published applications
- 50
- Assignees
- 25
- Inventors
- 70
- Latest grant
- 10 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 0 | 2 |
| 2009 | 2 | 2 |
| 2010 | 1 | 1 |
| 2011 | 3 | 4 |
| 2012 | 2 | 4 |
| 2013 | 2 | 2 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 2 | 1 |
| 2019 | 1 | 2 |
| 2020 | 1 | 3 |
| 2021 | 1 | 5 |
| 2022 | 2 | 3 |
| 2023 | 1 | 3 |
| 2024 | 1 | 4 |
| 2025 | 2 | 7 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Oncolytic virus platform to treat hematological cancer10 Mar 2026US 12,569,526 B2Arizona Board of Regents on behalf of Arizona State University
- Oncolytic virus expressing a car T cell target and uses thereof22 Jul 2025US 12,364,724 B2City of Hope
- Oncolytic virus platform to treat cancers with myxoma virus17 Jun 2025US 12,331,079 B2Arizona Board of Regents on behalf of Arizona State University
- Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors16 Jul 2024US 12,036,279 B2Memorial Sloan Kettering Cancer Center
- Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC28 Feb 2023US 11,591,616 B1Colorado State University Research Foundation
- Recombinant virus expressing interleukin-1212 Mar 2026US 2026/0071233 A1AstraZeneca AB
- Enhancing oncolytic virotherapy with a combination of nuclear export inhibitor and myxoma virus activating cell death pathways25 Dec 2025US 2025/0387443 A1Arizona Board of Regents on behalf of Arizona State University
- Oncolytic virus expressing a car t cell target and uses thereof18 Dec 2025US 2025/0381237 A1City of Hope
- Humanized recombinant vaccinia virus complement control protein (hrvcp) for protection of cognitive function9 Oct 2025US 2025/0312413 A1
- Therapeutic agent comprising multispecific antibody and use thereof in tumor therapy2 Oct 2025US 2025/0304690 A1Hangzhou Viromab Biotech Co., Ltd.
Most cited
By later US patents
- Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors15US 10,736,962 B2Memorial Sloan Kettering Cancer Center · 2020
- Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection5US 7,582,614 B2Robarts Research Institute · 2009
- Paramunity inducers based on attenuated rabbit myxoma virus4US 7,494,799 B2Bavarian Nordic A/S · 2009
- Monoparamunity inducers based on attenuated rabbit myxomaviruses4US 7,691,391 B2Bavarian Nordic A/S · 2010
- Oncolytic virus platform to treat cancers with myxoma virus3US 11,117,934 B2Arizona Board of Regents on behalf of Arizona State University · 2021